OMEROS CORPORATION

NASDAQ: OMER (Omeros Corporation)

Last update: 2 days ago, 3:27PM

3.05

-0.16 (-4.98%)

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Bullish
Biotechnology (Global) Bullish Bullish
Stock Omeros Corporation - -

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value

Ownership

Name Date Shares Held
Corient Private Wealth Llc 31 Dec 2023 663,663
Bank Of Montreal /Can/ 31 Dec 2023 563,096
Nomura Holdings Inc 31 Dec 2023 383,144

No data within this time range.

No data within this time range.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data